


## PHARMACEUTICAL 2022



## **NEKTAR THERAPEUTICS** Rank 292 of 475





## PHARMACEUTICAL 2022



## NEKTAR THERAPEUTICS Rank 292 of 475

The relative strengths and weaknesses of NEKTAR THERAPEUTICS are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEKTAR THERAPEUTICS compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 39% points. The greatest weakness of NEKTAR THERAPEUTICS is the variable Research and Development, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -178%, being 99% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	795,581
Cost of Goods Sold	24,897
Intangible Assets	76,501
Liabilities, Current	85,200
Liabilities, Non-Current	129,328
Other Assets	184,597
Other Compr. Net Income	-1,862
Other Expenses	557
Other Liabilities	223,153
Other Net Income	-77,177
Property and Equipment	60,510
Research and Development	400,269
Revenues	101,907
Selling, General and Administrative Expense	122,844

Output Variable	Value in 1000 USD
Assets	1,117,189
Liabilities	437,681
Expenses	548,567
Stockholders Equity	679,508
Net Income	-523,837
Comprehensive Net Income	-524,768
Economic Capital Ratio	-178%